Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder.
Amryt already had a licence to sell lomitapide in Europe and countries including Russia.
It said it would raise $60m in equity funding for the deal, which will create a group with combined proforma 2018 revenue of $136.5m.
Dr Joe Wiley, chief executive of Amryt, said the acquisition of Aegerion accelerates the company's ambition to become a global leader in treating rare conditions to help improve the lives of patients where there is a high unmet medical need.
"By delivering two substantial revenue-generating products and an enhanced pipeline of promising development opportunities, this will significantly strengthen our growth in highly attractive markets globally," he added.
